Tradewinds Capital Management’s Definium Therapeutics DFTX Stock Holding History

Tradewinds Capital Management’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-53	Closed	-$710	–	734
2025 Q4	$710	Hold	53	–	–	﹤0.01%	600
2025 Q3	$625	Hold	53	–	–	﹤0.01%	590
2025 Q2	$344	Hold	53	–	–	﹤0.01%	576
2025 Q1	$311	Hold	53	–	–	﹤0.01%	607
2024 Q4	$369	Hold	53	–	–	﹤0.01%	609
2024 Q3	$302	Hold	53	–	–	﹤0.01%	580
2024 Q2	$383	Hold	53	–	–	﹤0.01%	535
2024 Q1	$499	Hold	53	–	–	﹤0.01%	494
2023 Q4	$194	Hold	53	–	–	﹤0.01%	442
2023 Q3	$166	Hold	53	–	–	﹤0.01%	472
2023 Q2	$190	Hold	53	–	–	﹤0.01%	443
2023 Q1	$169	Sell	53 -101	-66%	-$336	﹤0.01%	453
2022 Q4	$339	Hold	154	–	–	﹤0.01%	457
2022 Q3	$1K	Buy	154 +1	+0.7%	+$10	﹤0.01%	378
2022 Q2	$1K	Hold	153	–	–	﹤0.01%	397
2022 Q1	$3K	Buy	153 +100	+189%	+$1.74K	﹤0.01%	628
2021 Q4	$1K	Hold	53	–	–	﹤0.01%	729
2021 Q3	$2K	Hold	53	–	–	﹤0.01%	659
2021 Q2	$3K	Buy	+53	New	+$2.78K	﹤0.01%	629

Other funds holding DFTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Tradewinds Capital Management's DFTX Position: Q1 2026 in Review

Tradewinds Capital Management sold out of Definium Therapeutics (DFTX) in Q1 2026, closing a stake of 53 shares — an estimated $710 sold.

Tradewinds Capital Management first reported a position in DFTX in Q2 2021 and held it in 19 quarters. The position peaked at $3K in Q1 2022. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

Tradewinds Capital Management reported no remaining Definium Therapeutics position as of Q1 2026 after selling out during the quarter.
Tradewinds Capital Management sold 53 Definium Therapeutics shares in Q1 2026, an estimated $710.
Tradewinds Capital Management first reported a position in Definium Therapeutics in Q2 2021 and held it in 19 quarters.
Tradewinds Capital Management's Definium Therapeutics position peaked at $3K in Q1 2022.
247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Tradewinds Capital Management's 13F filing for Q1 2026, filed 15 Apr 2026.